Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gefitinib
Drug ID BADD_D01008
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indications and Usage For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Marketing Status approved; investigational
ATC Code L01EB01
DrugBank ID DB00317
KEGG ID D01977
MeSH ID D000077156
PubChem ID 123631
TTD Drug ID D09XZB
NDC Product Code 61200-002; 65344-0029; 54245-1359; 60505-4512; 69339-168; 50742-366; 67184-0531; 0310-0482; 53104-7700; 63850-8070; 0480-4053; 68554-0060; 73377-128; 54893-0036
UNII S65743JHBS
Synonyms Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839
Chemical Information
Molecular Formula C22H24ClFN4O3
CAS Registry Number 184475-35-2
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eczema23.03.04.0060.000112%
Electrocardiogram QT prolonged13.14.05.004--
Epilepsy17.12.03.0020.000168%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.000604%
Erythema23.03.06.0010.000616%Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye disorder06.08.03.0010.000112%Not Available
Eye haemorrhage12.02.02.012; 24.07.05.002; 06.07.02.001--Not Available
Eye pain06.08.03.002--
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.0040.000224%
Gastric cancer16.13.03.001; 07.21.02.0010.000168%Not Available
Gastric ulcer07.04.03.0020.000168%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal necrosis24.04.08.006; 07.15.01.0030.000112%
Gastrointestinal pain07.01.05.005--
Gastrointestinal perforation07.04.04.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000112%
Haematemesis24.07.02.011; 07.12.02.0020.000224%Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.0060.000168%
Haemoglobin13.01.05.018--Not Available
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.0040.000392%Not Available
Haemorrhage subcutaneous24.07.06.010; 23.06.07.0020.000112%Not Available
Haemothorax12.01.18.005; 24.07.01.008; 22.05.02.0010.000168%
Hepatic cyst16.06.02.001; 09.01.08.0080.000112%Not Available
Hepatic failure09.01.03.0020.000224%
Hepatic function abnormal09.01.02.0010.001007%Not Available
Hepatitis09.01.07.0040.000168%Not Available
Hepatocellular injury09.01.07.0080.000112%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene